Autoimmune Diseases: Can CAR-Directed Cell Therapies Become Standard of Care?
Wednesday, May 29, 2024 02:15 PM - 03:15 PM
Room 212-214
Roundtable
Organized by: ISCT Clinical Translation Committee
Moderator
Key Learning Objectives
1. Market drivers and business model for the rising interest in autoimmune diseases using cell therapies
2. Differences in treating autoimmune diseases from oncological malignancies
3. Practical solutions for clinical study protocol design
Moderator
- Sudhakar Sridharan, MD, PPD, part of Thermo Fisher Scientific, United States
- Dominic Borie, MD, PhD, Kyverna Therapeutics, Inc., United States
- Dominique Farge, MD, PhD, St Louis Hospital Assistance Publique-Hôpitaux De Paris Paris-Cité University, France
- Mohammad Heidaran, PhD, Cellx Inc., United States
Key Learning Objectives
1. Market drivers and business model for the rising interest in autoimmune diseases using cell therapies
2. Differences in treating autoimmune diseases from oncological malignancies
3. Practical solutions for clinical study protocol design
Sudhakar Sridharan
Vice President, Medical Science & Strategy, PPD
PPD, Part of Thermo Fisher Scientific
Moderator
Vice President, Medical Science & Strategy, PPD
PPD, Part of Thermo Fisher Scientific
Moderator